Neuron-specific alterations in signal transduction pathways associated with Alzheimer's disease by Gerschütz, Anne et al.




Neuron-Specific Alterations in Signal
Transduction Pathways associated with
Alzheimer’s Disease
Anne Gerschütza, Helmut Heinsenb, Edna Grünblattc, Anne Kristin Wagnera, Jasmin Bartlc,
Christoph Meissnerd, Andreas J. Fallgattere, Safa Al-Sarrajf , Claire Troakesf , Isidro Ferrerg,
Thomas Arzbergerh, Jürgen Deckertb, Peter Riedererb, Matthias Fischerb, Thomas Tatschneri
and Camelia Maria Monoranua,∗
aDepartment of Neuropathology, Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany
bUniversity Hospital, Clinic and Policlinic for Psychiatry, Psychosomatic and Psychotherapy,
University of Wuerzburg, Wuerzburg, Germany
cClinic of Child and Adolescent Psychiatry, University of Zurich, Zurich, Switzerland
dDepartment of Forensic Medicine, University of Schleswig-Holstein, Luebeck, Germany
eClinic and Policlinic for Psychiatry and Psychotherapy, University of Tuebingen, Tuebingen, Germany
f MRC London Neurodegenerative Diseases Brain Bank, King’s College London, London, UK
gInstitut de Neuropatologia, Seervei Anatomia Patologica, IDIBELL-Hospital Universitari de Bellvitge,
Barcelona, Spain
hInstitute of Neuropathology and Prion Research, University of Munich, Munich, Germany
iInstitute of Legal Medicine, University of Wuerzburg, Wuerzburg, Germany
Accepted 5 November 2013
Abstract. The hallmarks of sporadic Alzheimer’s disease (AD) are extracellular amyloid deposits, intracellular neurofibrillary
tangles (NFTs), and neuronal death. Hyperphosphorylation of tau is a key factor in the generation of NFTs. Mitogen activated
protein kinase 1 (MAPK1) and protein kinase C beta (PRKCB) are thought to play a role in hyperphosphorylation, and PRCKB
is thought to be involved in hypoxic stress and vascular dysfunction, and to trigger MAPK phosphorylation pathways. We per-
formed single-cell analyses of neurons with different vulnerabilities to AD-related changes. Using quantitative PCR (qPCR), we
measured the levels of MAPK1 and PRKCB transcript in CA1 (high vulnerability), CA2 pyramidal cells from the hippocampus,
granule cells from the cerebellum (low vulnerability), and neurons from the brain stem (nucleus tractus spinalis nervi trigemini,
characterized by early neurophysiological deficits) at progressive Braak stages compared to age-matched controls. The highly
vulnerable CA1 pyramidal neurons were characterized by age- and disease-unrelated increases in PRCKB levels and by age- and
disease-related increases in MAPK1 levels. In contrast, low PRKCB levels were found in CA2 pyramidal neurons, and MAPK1
levels were elevated in controls and intermediate AD stages. Both PRKCB and MAPK1 were increased in the late AD stages.
MAPK1 and PRKCB levels were low in the brainstem and cerebellum. We propose that alterations in the expression of these
two genes occur early in the pathogenesis of AD in a region-specific manner. In addition, multiple signal transduction pathways
need to be affected to result in AD instead of physiological aging.
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INTRODUCTION
The neuropathological criteria for AD comprise
extracellular amyloid deposits, intracellular neu-
rofibrillary tangles (NFTs), and neuron loss. NFTs
propagate in an anatomically stereotypical manner,
allowing classification into different AD stages [1].
Closely related areas or fields within circumscribed
regions exhibit different susceptibilities to neuropatho-
logical changes. The CA1 region of the hippocampus is
especially vulnerable to AD-related changes, whereas
the nearby CA2 region [1, 2] displays no significant
loss of pyramidal cells during AD development [3].
The cerebellum is nearly devoid of NFTs and prone to
amyloid deposits, particularly in the molecular layer
[4–6]. Involvement of the brainstem in AD is contro-
versial. Some studies have reported that certain nuclei
of the brain stem are affected early in AD [7–9], but
other studies did not find evidence that AD progresses
from the subcortical to cortical brain regions [10]. A
diagnostic method for detecting AD in its early stages
uses vagus-evoked somatosensory potentials [11, 12].
The auricular branch of the vagus nerve is composed of
sensory fibers, some of which end in the nucleus tractus
spinalis nervi trigemini and are stimulated via electric
potentials [13]. Individuals with dementia demonstrate
longer latencies compared to age-matched controls,
suggesting involvement of the nucleus tractus spinalis
nervi trigemini in the development of AD.
The propensity of neuronal cells and regions to
react differently to identical pathogenic challenges was
called pathoklisis by Vogt and Vogt [14]. According
to the authors, pathoklisis represents a concept in the
study of the reaction of normal neurons to pathological
events. In our special case, we wanted to unravel the
potential molecular mechanisms underlying the emer-
gence of tau pathology.
The reasons for the selective vulnerability of cer-
tain brain regions and within individual cell types
are still unknown. We focused on two impor-
tant components of signal transduction pathways
that are associated with early AD development:
mitogen-activated protein kinase 1 (MAPK1) and
protein kinase C beta (PRKCB). MAPKs are serine-
threonine kinases involved in the mediation of cellular
responses, including cell proliferation, differentiation,
cell survival, and apoptosis. The mammalian MAPK
family includes extracellular signal-regulated kinases
(MAPK1, MAPK2), p38, and c-Jun NH2-terminal
kinase (JNK). Each of these kinases is capable of phos-
phorylating tau protein. MAPK1 mRNA and activated
protein levels are upregulated in the hippocampus in
AD [15–17], implicating MAPK1 in the formation of
hyperphosphorylated tau protein early in the develop-
ment of AD.
Protein kinase C (PKC) comprises a family
of related serine-threonine kinases. One isoform,
PRKCB, is fully activated through the second mes-
sengers CA2+ and diacylglycerol (DAG), and deficits
in signaling are linked to AD progression. Divergent
opinions exist regarding the involvement of PRKCB
in AD development. Some investigators have reported
deficiencies in PKC activation [18, 19], whereas others
have reported an increase in phosphorylated PKC [20].
Using single-cell laser microdissection, we exam-
ined mRNA levels in neurons from the CA1 and CA2
regions of the hippocampus, nucleus tractus spinalis
nervi trigemini of the brain stem, and cerebellum of
AD patients. The measurements were compared to age-
matched controls in order to obtain new insights into
the pathogenesis and progression of AD.
METHODS
Tissue samples
Frozen brain tissue (hippocampus, brain stem, and
cerebellum) from patients clinically and neuropatho-
logically diagnosed with different stages of AD and
age-matched controls were provided by four differ-
ent Brain Bank Centers (Wuerzburg, Munich, King’s
College London, and Barcelona). All tissue banks are
members of the BrainNet Europe Brain Bank Consor-
tium Network (http://www.brainnet-europe.org/). The
tissue samples were snap-frozen on dry ice. Samples
were categorized as controls (n = 9; no neuropatho-
logically diagnosed Braak stages or Braak stage I),
intermediate AD (n = 11; Braak stages III–IV), or
late AD (n = 9; Braak stages V–VI). The postmortem
intervals (PMIs) varied from 2 to 72 h but were not sig-
nificantly different between groups: mean ± standard
deviation (SD) 26.1 ± 21.8 h in the control group,
32.0 ± 16.7 h in the intermediate AD group, and
26.5 ± 12.3 h in the late AD group. The age range was
62–80 years in controls, 64–92 years in the intermedi-
ate AD group, and 56–86 years in the late AD group.
Significant age differences were found between the
control and intermediate AD groups (69.2 ± 5.0 years
versus 79.5 ± 7.1 years, p < 0.0001) and between the
intermediate and late AD groups (79.5 ± 7.1 years ver-
sus 72.2 ± 9.6 years, p = 0.0001). Demographic details
are provided in Table 1. The study was approved by the
local ethics committee (Application Number 99/11)
and was performed in accordance with the ethical
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Table 1
Sample characteristics
No. Group Age (y) PMI (h) Gender Braak stage RIN
1 Control 80 23 m I 6.4
2 Control 70 40 f I 6.8
3 Control 62 48 f I 6.3
4 Control 68 11 m I 5.8
5 Control 70 2 m I 7.6
6 Control 67 15 m I 6.9
7 Control 64 9 m I 6.1
8 Control 73 16 f I 5.6
9 Control 69 72 m – 6.7
Mean – 69.2 26.1 f/m = 0.5 –/I 6.5
SD – 5.0∗∗ 21.8 – – 0.6
10 Intermediate AD 77 24 f III 6.3
11 Intermediate AD 78 38 f IV 6.6
12 Intermediate AD 75 20 f III 6.5
13 Intermediate AD 85 46 f III 5.9
14 Intermediate AD 64 24 m III 6.6
15 Intermediate AD 80 60 m III 6.2
16 Intermediate AD 92 20 f III 4.8
17 Intermediate AD 85 25 m IV 5.6
18 Intermediate AD 86 61 f III 5.4
19 Intermediate AD 76 6 m III 5.8
20 Intermediate AD 77 28 f III 5.1
Mean – 79.5 32.0 f/m = 1.75 III–IV 5.9
SD – 7.1 16.7 – – 0.6
21 Late AD 74 26 f V 5.1
22 Late AD 65 24 f V 4.8
23 Late AD 80 24 f VI 6.8
24 Late AD 83 22 f VI 6.0
25 Late AD 70 39 m VI 5.2
26 Late AD 62 n.a. m VI 6.5
27 Late AD 74 50 m VI 5.4
28 Late AD 86 21 f VI 7.2
29 Late AD 56 7 f VI 5.1
Mean – 72.2 26.5 f/m = 2 V–VI 5.8
SD – 9.6∗∗ 12.3 – – 0.9
AD, Alzheimer’s disease; f, female; m, male; n.a., not available;
PMI, postmortem interval; RIN, RNA integrity number; SD, stan-
dard deviation. ∗∗p < 0.001 versus Intermediate AD using ANOVA
with post-hoc Scheffe test.
standards described in the most recent version of the
Declaration of Helsinki.
Tissue quality
Various factors, including long PMI intervals, can
lead to a reduction in tissue, and consequently RNA,
quality. To analyze RNA quality, total RNA was
extracted from 2–3 brain slices (10-m thickness)
for each included case using the RNeasy Min Elute
Cleanup Kit (Qiagen, Hilden, Germany). The RNA
concentration was measured using a spectrophotome-
ter (Nanodrop 1000, Peqlab, Erlangen, Germany). A
2-l aliquot of the isolated RNA was delivered to
the Microarray Core Unit in Wuerzburg. The RNA
integrity number (RIN) was determined using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Boe-
blingen, Germany). Only cases with a RIN close to
or higher than 5 were included in the study to ensure
sufficient RNA quality.
Sample preparation for laser microdissection
Ten-micrometer sections were cut from each brain
region using a CM1950 cryostat (Leica, Wetzlar, Ger-
many) at −15◦C, and then mounted on polyester
membranes (Leica, Wetzlar, Germany) and stained
with cresyl violet as follows. The sections were fixed
for 2 min in 70% EtOH, stained in 1% cresyl violet
for 1 min, and washed in 70% and 100% EtOH. The
slides were allowed to dry completely in a desiccator
for 45 min and then used directly for laser microdis-
section or stored at −80◦C until needed for further
processing.
Laser microdissection and cDNA synthesis
The slides were used for laser microdissection on a
LMD6000 microscope (Leica). In each case, a total of
150 pyramidal cells from the CA1 and CA2 regions
of the hippocampus, 500 neurons from among the
diverse neuronal types of the nucleus tractus spinalis
nervi trigemini of the brain stem, and 500 cerebellar
granule cells respectively were laser microdissected.
Next, 4.7 l of a combined cell lysis and cDNA syn-
thesis reaction mix consisting of 1 mM Tris/HCl (pH
8.0), 0.2 mM dNTPs (VWR, Darmstadt, Germany),
0.1 mM Random Primer N6 (Roche, Mannheim, Ger-
many), 1 × First Strand Buffer (Invitrogen, Darmstadt,
Germany), 10 mM dithiothreitol (Life Technologies,
Darmstadt, Germany), 0.5% Nonident P40 (Roche),
20 g glycogen (Fermentas, St. Leon-Rot, Germany),
and 5 Units RNasin Plus RNase Inhibitor (Promega,
Mannheim, Germany) was added directly to the cells
following a modification of the protocol described by
Grundemann et al. [21]. The cap was incubated upside
down for 2 min at 72◦C and then 1 min on ice, followed
by centrifugation for 1 min at full speed. Superscript
III reverse transcriptase (60 U in 0.3 l) was added to
each reaction. The cDNA synthesis was performed for
2 h at 38◦C and 8 h at 39◦C in a final volume of 5 l.
The cDNA was stored at −20◦C.
Real-time quantitative polymerase chain reaction
(qPCR)
The qPCR reactions were carried out using 1 l
diluted cDNA (1 : 10), Gene Expression MasterMix
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(Life Technologies), and predesigned TaqMan assays
(Life Technologies, Darmstadt, Germany) in a total
volume of 13 l in a CFX C1000TM real time system
(BioRad, Muenchen, Germany). The TaqMan assays
were MAPK1 (Life Technologies, Hs01046830 m1)
and PRKCB (Life Technologies, Hs00176998 m1).
A multiple gene set was included to allow the
detection of suitable reference genes for normal-
ization: glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; Life Technologies, Hs99999905 m1),
solute carrier family 1 member 3 (SLC1A3; Life
Technologies, Hs00188193 m1), mitochondrial
single-stranded DNA binding protein 1 (SSBP1;
Life Technologies, Hs00995378 m1), TAO kinase
3 (TAOK3; Life Technologies, Hs00937694 m1),
TATA box binding protein (TBP; Life Technologies,
Hs00427620 m1), transmembrane 9 superfamily
protein member 4 (TM9SF4; Life Technologies,
Hs00207196 m1), TM2 domain containing 1
(TM2D1; Life Technologies, Hs00608855 m1), and
zinc finger protein 445 (ZNF445; Life Technologies,
Hs00412938 m1). All assays were FAM-labeled, and
only intron-spanning assays were used to avoid the
detection of genomic DNA. Each assay included a
negative cDNA synthesis reaction without reverse
transcriptase that resulted in no detectable signals
after qPCR (data not shown). The run conditions
consisted of an initial phase of 50◦C for 2 min, 95◦C
for 10 min, and 50 cycles including a 15 s denaturation
step at 95◦C and primer annealing and elongation for
1 min at 60◦C. Each sample was tested in triplicate
with mean values calculated at the end of the run.
Technical replicates of different dilutions were
performed to test the acceptable variations between
the Cq-values of one sample when using a low
concentration of cDNA. Non-template controls were
included that resulted in no signals. For normalization,
the individual PCR efficiency of each primer pair
was defined using LinReg [22] (Table 2). GeNorm
(http://medgen.ugent.be/jvdesomp/genorm/) was used
to detect the most stable reference genes. GAPDH and
TM2D1 displayed the lowest M-values (both 0.678)
and were used as reference genes for normalization.
After calculating the geometric averages of the
quantities of the reference genes for each sample,
the normalized expression levels were assessed by
dividing the quantities of the gene of interest for
each sample by the corresponding normalization
factor generated by GeNorm (Microsoft Excel 2007).
Samples with no qPCR signal for reference or target
genes and samples with a variation higher than 2-SD
were defined as outliers and excluded from analysis.
Table 2
PCR efficiency determined by LinReg












Statistical analysis of MAPK1 and PRKCB expres-
sion within the different groups and brain regions
was performed using one-way analysis of variance
(ANOVA) and the post hoc Scheffe test (StatView 5.0).
Significance was set at p < 0.05.
RESULTS
MAPK1 expression in age and AD
Because we found significant age differences
between the control and intermediate AD groups,
we tested whether an age-related expression pattern
exists for MAPK1. No linear correlation was observed
between MAPK1 expression and age within the groups
using Fisher transformation (data not shown). Fig-
ure 1A shows the MAPK1 expression levels in each
region by group. Significant differences were observed
between groups for only the CA2 pyramidal cells of the
hippocampus; MAPK1 expression was significantly
higher in the late AD group compared to the control
(p = 0.02) and intermediate AD group (p = 0.015). Fig-
ure 1B shows the MAPK1 expression pattern within
the neurons from different brain regions independent
of group. MAPK1 expression was significantly higher
in CA1 pyramidal cells from the hippocampus than
in the granule cells from the cerebellum (p < 0.0001)
or neurons from the brain stem (p < 0.0001). MAPK1
expression was also significantly higher in neurons
from the pyramidal layer of the CA2 region compared
to granule cells from the cerebellum (p < 0.0001) and
neurons from the brain stem (p < 0.0001). No signif-
icant differences were found in MAPK1 expression
between neurons from the cerebellum or brain stem or
between CA1 and CA2 pyramidal cells.
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Fig. 1. A) Expression of MAPK1 in granule cells from the cerebellum (Cb), CA1 and CA2 pyramidal cells from the hippocampus (CA1; CA2),
and neurons from the nucleus tractus spinalis of the brain stem (Bs) of control (dark grey; n = 8 for CA1, n = 8 for CA2, n = 9 for Bs, and n = 6
for Cb), intermediate AD (light grey; n = 11 for CA1, n = 11 for CA2, n = 8 for Bs, and n = 9 for Cb), and late AD (white; n = 8 for CA1, n = 9
for CA2, n = 7 for Bs, and n = 7 for Cb) groups. (B) Region-specific gene expression levels independent of group (n = 27 for CA1, n = 28 for
CA2, n = 24 for Bs, and n = 22 for Cb). Error bars indicate standard deviations. Statistical analysis was performed using ANOVA and the post
hoc Scheffe test. ∗p < 0.05, ∗∗p < 0.001.
PRKCB expression in age and AD
We did not detect an age-associated pattern of
PRKCB expression between the different groups when
using Fisher transformation (data not shown). Fig-
ure 2A shows the PRKCB expression levels in each
region by group. Significant differences were observed
between groups for only the CA2 region of the
hippocampus; PRKCB expression was significantly
higher in the late AD group compared to the control
(p = 0.045) and intermediate AD groups (p = 0.0005).
Independent of groups, the highest PRKCB expres-
sion was found in the pyramidal cells of the CA1
region (Fig. 2B). PRKCB expression levels were sig-
nificantly higher in the CA1 pyramidal cells compared
to CA2 pyramidal cells (p < 0.0001), cerebellar gran-
ule cells (p < 0.0001), and neurons from the brain
stem (p < 0.0001). Moreover, PRKCB expression was
significantly higher in neurons from the brain stem
compared to cerebellar granule cells (p = 0.0355). No
significant differences in PRKCB expression were
found between neurons from the CA2 region and neu-
rons from the cerebellum or brain stem.
No gender related variations in the expression of
MAPK1 and PRKCB were observed (data not shown).
DISCUSSION
We analyzed the MAPK1 and PRKCB expression
in neuronal cell types from different brain regions
with selective vulnerability to tau pathology over the
course of AD progression. The results suggest that
CA1 pyramidal cells express significantly higher lev-
els of MAPK1 and PRKCB transcript compared to
the cerebellar and brainstem regions. CA2 pyramidal
cells achieve an intermediate position in this rank-
ing, with elevated levels of MAPK1 and low levels
of PRKCB. However, data pooling masked the signif-
icantly elevated MAPK1 and PRKCB levels in CA2
pyramidal cells in the late stages of AD. Therefore,
when combined with the neuropathological observa-
tion, the elevated levels of MAPK1 and PRCKB could
be hypothesized to play a role in early NFT genesis in
CA1 pyramidal cells. The upregulation of both kinases
could play a role in NFT genesis in CA2 pyramidal
cells, but only in late stages of AD. The brainstem
regions with notoriously low levels of both kinases are
not prone to AD-related changes. Similarly, the cere-
bellum is only rarely, if ever, affected by AD-related
changes, and no abnormal activation of MAPK1 has
been observed in cerebellar tissue [23].
Variations in the expression of components of the
essential signal transduction pathways could explain
the different susceptibilities of certain cell types to
AD-related pathological changes. Previous immuno-
histochemistry studies have reported an association
between phosphorylated MAPK1 and early tau deposi-
tion [16]. Pei et al. [17] reported that activated MAPK1
accumulates in neurons without tau pathology as early
as Braak stages I and II, analogously increasing with
AD progression. MAPKs possess the capacity to phos-
phorylate tau in vitro and in vivo, and the involvement
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Fig. 2. A) Expression of PRKCB in granule cells from the cerebellum (Cb), pyramidal cells from the CA1 and CA2 regions of the hippocampus
(CA1; CA2), and neurons from the nucleus tractus spinalis of the brain stem (Bs) of control (dark grey; n = 8 for CA1, n = 7 for CA2, n = 8 for
Bs, and n = 6 for Cb), intermediate AD (light grey; n = 11 for CA1, n = 11 for CA2, n = 8 for Bs, and n = 8 for Cb), and late AD (white; n = 8 for
CA1, n = 8 for CA2, n = 7 for Bs, and n = 7 for Cb) groups. (B) Region-specific gene expression levels independent of group (n = 27 for CA1,
n = 26 for CA2, n = 23 for Bs, and n = 21 for Cb). Error bars indicate standard deviations. Statistical analysis was performed using ANOVA and
the post hoc Scheffe test. ∗p < 0.05, ∗∗p < 0.001.
of MAPK1 in the hyperphosphorylation of tau pro-
tein in AD has been hypothesized by other authors
[24–26]. The increased expression of MAPK1 in CA1
pyramidal cells could be one factor contributing to the
hyperphosphorylation of tau filaments.
Even though the CA2 region is not characterized
by early intracellular tau accumulation or neuron loss
in the context of AD, CA2 pyramidal cells expressed
identical levels of MAPK1 as CA1 pyramidal cells.
Therefore, the elevated expression of MAPK1 cannot
be the only explanation for the selective vulnerability
of CA1 pyramidal cells to AD-related changes.
The role of PRKCB in AD development is ambigu-
ous. Previous studies revealed a decrease in activated
PRKCB in particulate fractions from AD brains and
an increase in the soluble activated enzyme [27, 28].
These inconsistencies can be explained by the exper-
imental protocol for analyzing tissue homogenates,
whereas we focused on single-cell laser microdissec-
tion. Alldred et al. [29] also reported reduced PRKCB
levels in a mouse model of AD. This finding could
represent species-specific differences because the pri-
mate CA1 region consists of two layers: a superficial
and a deep pyramidal cell layer [30]. The pyramidal
cells of the deep layer, which is only present in pri-
mates, are prone to AD changes, whereas the cells of
the superficial layer are chromophilic and look sim-
ilar to CA2 pyramidal cells. In addition, the CA1
and CA2 borders are difficult to delineate in rodents.
Ginsberg et al. [31] obtained different molecular sig-
natures when analyzing single cells embedded in the
surrounding tissue. Staining frozen sections with cre-
syl violet guaranteed the harvest of neurons free of glial
cells and surrounding neuropil.
The elevated PRKCB mRNA levels could represent
reactions to acute and chronic stress, particularly in
association with vascular events [32]. Interestingly,
PRKCB activities are funneled into ERK/MAPK1
pathways via RAF and MEK [33]. Our pooled data
indicate significantly higher levels of PRKCB in neu-
rons from the nucleus tractus spinalis nervi trigemini
compared to granule cells. However, exclusive ele-
vation of PRKCB activity is not sufficient to cause
AD-related changes. Only a combined elevation of
MAPK1 and PRKCB-induced MAPK1 activity can
trigger hyperphosphorylation of tau and intracellular
deposition of NFT. Taken together, the results of the
present study demonstrate that certain neuronal cell
types in the brain display changes in essential sig-
nal transduction pathways. However, our data do not
provide evidence of early involvement of the nucleus
tractus spinalis nervi trigemini in the pathogenesis of
AD. Altered neurophysiological signals can also be
deduced from higher-order brainstem nuclei, includ-
ing the parabrachial nuclei, which are located close
to the nucleus tractus spinalis nervi trigemini that
receive collaterals from the ascending spinothalamic
tract, and also most likely from cutaneous vagal fibers.
The parabrachial nuclei are affected early in AD [34].
We could not discriminate between control and AD
cases, suggesting that alterations in signaling pathway
components occur in both aging individuals and early
in AD development. As the CA1 pyramidal cells of the
hippocampus exhibit increased mRNA levels for both
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MAPK1 and PRKCB, we propose that an alteration in
at least two, or even multiple, signal transduction path-
ways is required for the pathological changes observed
in AD.
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